Compounds > 2',3'-dideoxyuridine
Page last updated: 2024-09-23

2',3'-dideoxyuridine

Cross-References

ID SourceID
PubMed CID65161
CHEMBL ID1468
CHEBI ID183866
SCHEMBL ID8715
MeSH IDM0165529

Synonyms (28)

Synonym
BIDD:GT0651
5983-09-5
uridine, 2',3'-dideoxy-
ddurd
1-[(2r,5s)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
2',3'-dideoxyuridine ,
2',3'-dideoxyuridine, 98%
CHEMBL1468
1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
AKOS015907691
2',3'-dideoxy uridine
AM83954
SCHEMBL8715
BTOTXLJHDSNXMW-POYBYMJQSA-N
2',3'-dideoxy-uridine
dideoxyuridine
1-(2',3'-dideoxy-beta-ribofuranosyl)uracil
W-200600
AC-32185
DTXSID90208558
2,3-dideoxyuridine
1-((2r,5s)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
CS-W015022
F12171
DS-14365
CHEBI:183866
HY-W014306
PD166046

Drug Classes (1)

ClassDescription
pyrimidine 2',3'-dideoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID423784Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Aryl nucleoside H-phosphonates. Part 16: synthesis and anti-HIV-1 activity of di-aryl nucleoside phosphotriesters.
AID423782Cytotoxicity against human MT4 cells after 96 hrs by MTT assay2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Aryl nucleoside H-phosphonates. Part 16: synthesis and anti-HIV-1 activity of di-aryl nucleoside phosphotriesters.
AID423783Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Aryl nucleoside H-phosphonates. Part 16: synthesis and anti-HIV-1 activity of di-aryl nucleoside phosphotriesters.
AID125177In vitro inhibitory activity against Moloney murine leukemia virus (M-MULV) replication, a mammalian T-lymphotropic retrovirus1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
AID299251Inhibition of HIV1-induced cytopathogenicity in CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID154959Antiviral activity against HIV I strain (LAV) in human peripheral blood mononuclear (PBM) cells1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
AID299252Inhibition of HIV2-induced cytopathogenicity in CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID299253Cytotoxicity against CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID152643Cytotoxic effect in uninfected human peripheral blood mononuclear (PBM) cells; Not determined1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (25.00)18.7374
1990's3 (25.00)18.2507
2000's3 (25.00)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
stavudine[no description available]medium40dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zidovudine[no description available]medium50azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
3'-azido-2',3'-dideoxyuridine[no description available]medium20
3'-azido-2',3'-dideoxy-5-bromouridine[no description available]medium20
3'-azido-2',3'-dideoxy-5-methylcytidine[no description available]medium20
2',3'-dideoxythymidine[no description available]medium20
2',3'-didehydro-2',3'-dideoxyuridine[no description available]medium50
5'-amino-2',5'-dideoxythymidine[no description available]medium20
3'-amino-2',3'-dideoxythymidine[no description available]medium20
3'-amino-2',3'-dideoxyuridine[no description available]medium10
3'-azido-2',3'-dideoxycytidine[no description available]medium20
zalcitabine[no description available]medium20pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
2',3'-dideoxycytidinene[no description available]medium10
5-bromo-2',3'-dideoxyuridine[no description available]medium10
dideoxyadenosine[no description available]medium20adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
phosphoramidic acid[no description available]medium20phosphoric acid derivative
organophosphonates[no description available]medium10divalent inorganic anion;
phosphite ion
alpha-aminopyridine[no description available]medium10
pyrophosphate[no description available]medium10diphosphate ion
3'-fluoro-2',3'-dideoxyuridine[no description available]medium10
deoxycytidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymidine monophosphate[no description available]medium10thymidine 5'-monophosphatefundamental metabolite
uridine[no description available]medium10uridinesdrug metabolite;
fundamental metabolite;
human metabolite
thymidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
idoxuridine[no description available]medium10organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
fluorouracil[no description available]medium10nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
2',3'-dideoxyuridine-5'-triphosphate[no description available]medium10
didanosine[no description available]medium10purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
alovudine[no description available]low00pyrimidine 2',3'-dideoxyribonucleoside
3'-azido-3'-deoxy-5'-o-beta-glucopyranuronosylthymidine[no description available]low00pyrimidine 2',3'-dideoxyribonucleoside
ConditionIndicatedRelationship StrengthStudiesTrials
HIV0low30